Board Change at Hargreaves Lansdown plc
The Board of Hargreaves Lansdown plc is pleased to announce the appointment of Dan Olley as an Independent Non-Executive Director of Hargreaves Lansdown plc with effect from 1 June 2019. In addition to joining the Hargreaves Lansdown plc Board, Dan will also be a member of the Risk Committee.
Dan is a seasoned senior technology leader with a track record of driving digital transformations in established businesses, including financial services, insurance, business information solutions, research and healthcare. He brings a problem solving and analytical skill-set, along with experience of successfully implementing advanced technologies to drive both revenue growth and operational process efficiency and optimisation. Dan has operated in growth focused organisations and brought his expertise to technology leadership roles within small privately-held and large corporate organisations, by combining a high commercial awareness with a strong technical and product management background.
He is currently Executive Vice President and CTO at Elsevier, the largest division of RELX, the FTSE 15 information-based analytics company.
Dan will seek election by our shareholders at our forthcoming AGM on 10 October 2019.
Deanna Oppenheimer, Chair of Hargreaves Lansdown plc, said 'I'm delighted to welcome Dan to the Board. He brings a wealth of experience from a wide range of sectors, and will add further breadth to the knowledge base of the Board.'
As at 1 June 2019, Dan Olley has confirmed that he does not own shares in Hargreaves Lansdown PLC.
Other than the directorships disclosed above, there are no matters required by paragraphs LR 9.6.13R (1) to (6) of the listing rules to be disclosed.
For further information please contact:
Hargreaves Lansdown +44 (0) 117 988 9967
James Found, Investor Relations
Danny Cox, Media Relations
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.